Innovent’s Cyramza Gains NMPA Approval for Hepatocellular Carcinoma
Innovent Biologics Inc. (HKG: 1801) has announced that the supplementary Biologic License Application (sBLA) for...
Eli Lilly
Eli Lilly’s Retevmo Wins First China Approvals for RET-Driven Cancers
Eli Lilly & Co (NYSE: LLY) has secured its first approvals in China for Retevmo...
Eli Lilly Announces Global C-Suite Changes, New Leadership in China
US-based pharmaceutical giant Eli Lilly (NYSE: LLY) announced significant changes to its global C-suite. Julio...
Fudan-Zhangjiang’s JAK1 Inhibitor FZJ-003 Gel Enters Phase I Trial for Atopic Dermatitis
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I...
Jacobio Pharmaceuticals Doses First Patient in JAB-BX102 Phase I/IIa Trial for CD73-Targeted Cancer Therapy
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a...
Innovent Biologics Doses First Patient in Higher-Dose Mazdutide Obesity Trial
China’s Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in...
Boehringer, Eli Lilly’s Jardiance Wins NMPA Approval for Heart Failure with Preserved Ejection Fraction
Boehringer Ingelheim and Eli Lilly (NYSE: LLY) announced that China’s National Medical Products Administration (NMPA)...
Everest Medicines CEO Resigns as Trodelvy Sale Completed
China-based biotech Everest Medicines (HKG: 1952) announced the resignation of CEO Dr. Kerry Blanchard, effective...
Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...
Eli Lilly Reports First Quarterly Revenue Dip in Two Years, China Sales Plunge
US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a...
Eli Lilly Files for Baqsimi Approval in China to Treat Severe Hypoglycemia
Eli Lilly & Co. (NYSE: LLY) has submitted a market approval application to China’s Center...
Eli Lilly’s Taltz Wins Second NMPA Approval for Ankylosing Spondylitis
U.S. pharmaceutical giant Eli Lilly announced it has received a second marketing approval from the...
MabPharm’s CMAB015 Biosimilar Receives NMPA Approval for Clinical Study
Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...
Gan & Lee Pharmaceuticals Doses First Patient in GZR18 Phase II Study for Diabetes and Obesity
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
Eli Lilly’s Retevmo Wins Special Approval in China’s Lecheng Medical Pilot Zone
Eli Lilly & Co. (NYSE: LLY) has secured special approval for its RET kinase inhibitor...
Innovent Biologics’ Mazdutide Meets Phase II Goals in Type 2 Diabetes Study
China-based Innovent Biologics Inc. (HKG: 1801) announced that its Phase II study of mazdutide (IBI362/OXM3)...
Triastek Partners with Eli Lilly to Explore 3D Printing for GI Drug Delivery
China-based Triastek Inc., a pharmaceutical 3D printing specialist, announced a partnership with US firm Eli...
Eli Lilly’s Trulicity + Insulin Combo Meets Goals in China’s AWARD-CHN3 Study
Eli Lilly (NYSE: LLY) announced that its Phase III AWARD-CHN3 study of Trulicity (dulaglutide) combined...
Eli Lilly’s Donanemab Receives Tacit Approval for Alzheimer’s Clinical Trial in China
The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY)...
Innovent Biologics’ Tyvyt Approved for First-Line Esophageal Squamous Cell Carcinoma
The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801)...